BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De Sells 46,896 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 46,896 shares of BioLife Solutions stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $23.43, for a total value of $1,098,773.28. Following the sale, the chief executive officer now owns 414,958 shares of the company’s stock, valued at approximately $9,722,465.94. This represents a 10.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

BioLife Solutions Trading Up 2.1 %

BLFS stock traded up $0.58 during trading on Wednesday, reaching $27.69. 270,111 shares of the stock traded hands, compared to its average volume of 217,162. The firm has a market capitalization of $1.28 billion, a PE ratio of -26.12 and a beta of 1.92. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The business’s 50 day moving average price is $25.91 and its 200-day moving average price is $24.27. BioLife Solutions, Inc. has a 52-week low of $14.50 and a 52-week high of $28.88.

Institutional Trading of BioLife Solutions

Institutional investors and hedge funds have recently bought and sold shares of the business. Fred Alger Management LLC increased its position in shares of BioLife Solutions by 6.0% in the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after acquiring an additional 88,840 shares in the last quarter. State Street Corp increased its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC raised its position in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of BioLife Solutions by 9.1% during the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after purchasing an additional 66,422 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its position in shares of BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after buying an additional 262,504 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BLFS. Craig Hallum boosted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Northland Securities boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday. Benchmark restated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.